Changes of P300 latency with age in childhood epilepsy

Pediatr Neurol. 1995 Feb;12(2):132-5. doi: 10.1016/0887-8994(95)00001-v.

Abstract

Auditory event-related potentials (P300 latency; odd-ball paradigm) were examined in 129 patients with childhood epilepsies and 53 controls. The P300 latency in the patients with epilepsies (373 +/- 39.4 ms) was significantly longer than in controls (356 +/- 38.4), and the prolongation was greatest in the patients with symptomatic partial epilepsies (390 +/- 40.5), mild in those with idiopathic generalized epilepsies (370 +/- 24.3), and minimum in those with idiopathic partial epilepsies (363 +/- 28.9). Abnormal P300 latency occurred at all ages during childhood in patients with symptomatic partial epilepsies, and at older ages in patients with idiopathic generalized epilepsies. The shortening of latency with age was relatively small in patients with epilepsies compared with controls. These results suggest that the prolongation of P300 latency (i.e., existence of cognitive disturbance) displays characteristic changes with age in each epileptic syndrome.

MeSH terms

  • Adolescent
  • Age Factors
  • Anticonvulsants / adverse effects
  • Anticonvulsants / therapeutic use
  • Arousal / drug effects
  • Arousal / physiology*
  • Attention / drug effects
  • Attention / physiology*
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / physiopathology
  • Child
  • Dominance, Cerebral / drug effects
  • Dominance, Cerebral / physiology
  • Electroencephalography* / drug effects
  • Epilepsies, Partial / diagnosis
  • Epilepsies, Partial / drug therapy
  • Epilepsies, Partial / physiopathology*
  • Epilepsy, Generalized / diagnosis
  • Epilepsy, Generalized / drug therapy
  • Epilepsy, Generalized / physiopathology*
  • Evoked Potentials, Auditory / drug effects
  • Evoked Potentials, Auditory / physiology*
  • Female
  • Humans
  • Male
  • Pitch Discrimination / drug effects
  • Pitch Discrimination / physiology
  • Reaction Time / drug effects
  • Reaction Time / physiology
  • Reference Values

Substances

  • Anticonvulsants